Effetto del lactobacillus paracasei I1688 e del lactobacillus salivarius I1794 (psmix®) sui lipidi ematici nell'ipercolesterolemia lieve

Translated title of the contribution: Effect of mixture 12: 1 lactobacillus paracasei I1688 and of lactobacillus salivarius I1794 (psmix®) on lipids in mild hypercholesterolemia

Roberto Fogari, Amedeo Mugellini, Tara Santoro, Ilaria Ferrari, Giuseppa Derosa

Research output: Contribution to journalArticle

Abstract

The purpose of this study was to test the effect on hypercholesterolemia after the assumption of PSmix (Fiorilac® PS) in patient with mild hypercholesterolemia. The study population was aged between 35 and 65 years, affected by mild hypercholesterolemia (200-250 mg/dL) and never treated. Exclusion criteria were familial hypercholesterolemia, diabetes, ischemic heart disease, heart failure, previous stroke, high consumption of alcohol and/or concomitant treatment with diuretics and/or thyroid hormones. Thirty-eight patients were recruited into the study. After two weeks pre-treatment, patients fulfilling the inclusion criteria were instructed to assume daily PSmix for 12 weeks. The dietary habits of the patients were monitored using a questionnaire, but not modified by physicians; they also reported the use of drugs. After two weeks pre-treatment and after twelve weeks active treatment were evaluated plasma levels of total cholesterol (TC), HDL cholesterol (HDL-C) and triglycerides (Tg). LDL cholesterol (LDL-C) was calculated using the Friedewald formula. This study suggests that oral administration of PSmix is effective in improving lipid parameters in patients with mild hypercholesterolemia. It induces a modest but significant reduction in TC (8,6%, -18.4 mg/dl;

Original languageItalian
Pages (from-to)107-111
Number of pages5
JournalTrends in Medicine
Volume10
Issue number2
Publication statusPublished - Apr 2010

Fingerprint

Hypercholesterolemia
Lipids
Cholesterol
Hyperlipoproteinemia Type II
Feeding Behavior
Therapeutics
Thyroid Hormones
Diuretics
Alcohol Drinking
LDL Cholesterol
HDL Cholesterol
Myocardial Ischemia
Oral Administration
Triglycerides
Heart Failure
Stroke
Lactobacillus salivarius
Lactobacillus paracasei
Physicians
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Internal Medicine
  • Pharmacology (medical)

Cite this

@article{35d480357c1d4191a38b838ce60dd40b,
title = "Effetto del lactobacillus paracasei I1688 e del lactobacillus salivarius I1794 (psmix{\circledR}) sui lipidi ematici nell'ipercolesterolemia lieve",
abstract = "The purpose of this study was to test the effect on hypercholesterolemia after the assumption of PSmix (Fiorilac{\circledR} PS) in patient with mild hypercholesterolemia. The study population was aged between 35 and 65 years, affected by mild hypercholesterolemia (200-250 mg/dL) and never treated. Exclusion criteria were familial hypercholesterolemia, diabetes, ischemic heart disease, heart failure, previous stroke, high consumption of alcohol and/or concomitant treatment with diuretics and/or thyroid hormones. Thirty-eight patients were recruited into the study. After two weeks pre-treatment, patients fulfilling the inclusion criteria were instructed to assume daily PSmix for 12 weeks. The dietary habits of the patients were monitored using a questionnaire, but not modified by physicians; they also reported the use of drugs. After two weeks pre-treatment and after twelve weeks active treatment were evaluated plasma levels of total cholesterol (TC), HDL cholesterol (HDL-C) and triglycerides (Tg). LDL cholesterol (LDL-C) was calculated using the Friedewald formula. This study suggests that oral administration of PSmix is effective in improving lipid parameters in patients with mild hypercholesterolemia. It induces a modest but significant reduction in TC (8,6{\%}, -18.4 mg/dl;",
keywords = "Hypercholesterolemia, Lactobacilli, LDL, Probiotics, PSmix",
author = "Roberto Fogari and Amedeo Mugellini and Tara Santoro and Ilaria Ferrari and Giuseppa Derosa",
year = "2010",
month = "4",
language = "Italian",
volume = "10",
pages = "107--111",
journal = "Trends in Medicine",
issn = "1594-2848",
publisher = "Pharma Project Group Edizioni Scientifiche (PPG)",
number = "2",

}

TY - JOUR

T1 - Effetto del lactobacillus paracasei I1688 e del lactobacillus salivarius I1794 (psmix®) sui lipidi ematici nell'ipercolesterolemia lieve

AU - Fogari, Roberto

AU - Mugellini, Amedeo

AU - Santoro, Tara

AU - Ferrari, Ilaria

AU - Derosa, Giuseppa

PY - 2010/4

Y1 - 2010/4

N2 - The purpose of this study was to test the effect on hypercholesterolemia after the assumption of PSmix (Fiorilac® PS) in patient with mild hypercholesterolemia. The study population was aged between 35 and 65 years, affected by mild hypercholesterolemia (200-250 mg/dL) and never treated. Exclusion criteria were familial hypercholesterolemia, diabetes, ischemic heart disease, heart failure, previous stroke, high consumption of alcohol and/or concomitant treatment with diuretics and/or thyroid hormones. Thirty-eight patients were recruited into the study. After two weeks pre-treatment, patients fulfilling the inclusion criteria were instructed to assume daily PSmix for 12 weeks. The dietary habits of the patients were monitored using a questionnaire, but not modified by physicians; they also reported the use of drugs. After two weeks pre-treatment and after twelve weeks active treatment were evaluated plasma levels of total cholesterol (TC), HDL cholesterol (HDL-C) and triglycerides (Tg). LDL cholesterol (LDL-C) was calculated using the Friedewald formula. This study suggests that oral administration of PSmix is effective in improving lipid parameters in patients with mild hypercholesterolemia. It induces a modest but significant reduction in TC (8,6%, -18.4 mg/dl;

AB - The purpose of this study was to test the effect on hypercholesterolemia after the assumption of PSmix (Fiorilac® PS) in patient with mild hypercholesterolemia. The study population was aged between 35 and 65 years, affected by mild hypercholesterolemia (200-250 mg/dL) and never treated. Exclusion criteria were familial hypercholesterolemia, diabetes, ischemic heart disease, heart failure, previous stroke, high consumption of alcohol and/or concomitant treatment with diuretics and/or thyroid hormones. Thirty-eight patients were recruited into the study. After two weeks pre-treatment, patients fulfilling the inclusion criteria were instructed to assume daily PSmix for 12 weeks. The dietary habits of the patients were monitored using a questionnaire, but not modified by physicians; they also reported the use of drugs. After two weeks pre-treatment and after twelve weeks active treatment were evaluated plasma levels of total cholesterol (TC), HDL cholesterol (HDL-C) and triglycerides (Tg). LDL cholesterol (LDL-C) was calculated using the Friedewald formula. This study suggests that oral administration of PSmix is effective in improving lipid parameters in patients with mild hypercholesterolemia. It induces a modest but significant reduction in TC (8,6%, -18.4 mg/dl;

KW - Hypercholesterolemia

KW - Lactobacilli

KW - LDL

KW - Probiotics

KW - PSmix

UR - http://www.scopus.com/inward/record.url?scp=77956929677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956929677&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:77956929677

VL - 10

SP - 107

EP - 111

JO - Trends in Medicine

JF - Trends in Medicine

SN - 1594-2848

IS - 2

ER -